News & Media
September 26 2024
NextRNA Therapeutics Expands Executive Team with Appointment of Jesse Smith, PhD as Chief Scientific Officer
More
August 28 2024
Bayer and NextRNA Therapeutics enter strategic collaboration to develop small molecules targeting long non-coding RNAs (lncRNAs) in Oncology
More
September 26 2023
NextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD
More
December 08 2022
NextRNA Therapeutics to Participate in Upcoming 5th Annual RNA-Targeted Drug Discovery Summit
More
September 22 2022
NextRNA Therapeutics to Participate in Upcoming BioPharm America and Chardan’s 6th Annual Genetic Medicines Conference
More
August 11 2022
NextRNA Therapeutics names Dominique Verhelle as CEO and expands leadership team
More
March 01 2022
NextRNA Launches with $56 Million in Funding to Bring Transformative Non-coding RNA-directed Medicines to Patients
More
October 23 2024
The ‘Junk’ Genome May Actually Unlock The Next Cancer Treatment
More
September 10 2024
Long non-coding RNAs: what’s behind the growing “dark genome” buzz?
More
September 04 2024
Bayer and NextRNA sign $500M+ lncRNA oncology deal
More
August 28 2024
Bayer pens $547M biobucks pact with biotech pushing the boundaries of noncoding RNA FierceBiotech
More
August 28 2024
Bayer partners with NextRNA on lncRNA-targeted small molecules for cancer
More
August 28 2024
Bayer partners with RNA drugmaker to develop new cancer therapies
More
August 28 2024
Bayer signs $547 million pact with NextRNA in oncology push
More
August 28 2024
Boston biotech signs deal with Bayer worth up to $547 million
More
July 10 2023
The Long and Short of It: Exploring the Therapeutic Potential of lncRNAs
Q&A with Rory Johnson, PhD
More
June 21 2023
The Long and Short of It: Exploring the Therapeutic Potential of lncRNAs
Q&A with Susan Carpenter, PhD
More
June 06 2023
The Long and Short of It: Exploring the Therapeutic Potential of lncRNAs
Q&A with John Mattick, PhD
More